高盛：内地CDMO板块稳健看好药明康德(02359)、凯莱英(06821)等_老虎社区_美港股上老虎

高盛：内地CDMO板块稳健看好药明康德(02359)、凯莱英(06821)等

智通财经04-27

智通财经APP获悉，高盛就内地医药行业发布研报称，CDMO企业的业绩反映该板块的周期维持稳健，能见度日益取决于后期及商业化项目的敞口，而非早期融资条件。而AI亦未有对订单量、订单积压质量或定价造成结构性破坏。相反，医疗器械与医疗服务企业的业绩印证了不同股份的复苏进度参差。虽然大部分集中带量采购(VBP)与医保支付方式改革(DRG/DIP)的阻力似乎已被消化，但销量复苏、定价能力与盈利能见度仍存在...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2630364329?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-04-27 17:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2630364329","market":"sh","top_or_hot":-1,"title":"高盛：内地CDMO板块稳健 看好药明康德(02359)、凯莱英(06821)等","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，高盛就内地医药行业发布研报称，CDMO企业的业绩反映该板块的周期维持稳健，能见度日益取决于后期及商业化项目的敞口，而非早期融资条件。而AI亦未有对订单量、订单积压质量或定价造成结构性破坏。相反，医疗器械与医疗服务企业的业绩印证了不同股份的复苏进度参差。虽然大部分集中带量采购(VBP)与医保支付方式改革(DRG/DIP)的阻力似乎已被消化，但销量复苏、定价能力与盈利能见度仍存在...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1434465.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>高盛：内地CDMO板块稳健 看好药明康德(02359)、凯莱英(06821)等</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n高盛：内地CDMO板块稳健 看好药明康德(02359)、凯莱英(06821)等\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-27 17:25 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1434465.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，高盛就内地医药行业发布研报称，CDMO企业的业绩反映该板块的周期维持稳健，能见度日益取决于后期及商业化项目的敞口，而非早期融资条件。而AI亦未有对订单量、订单积压质量或定价造成结构性破坏。相反，医疗器械与医疗服务企业的业绩印证了不同股份的复苏进度参差。虽然大部分集中带量采购(VBP)与医保支付方式改革(DRG/DIP)的阻力似乎已被消化，但销量复苏、定价能力与盈利能见度仍存在...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1434465.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06821","symbol_name":"凯莱英","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1434465.html","article_id":"2630364329","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2630364329","pubTimestamp":1777281907,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"股份方面，该行对评级为“买入”的股份持更正面态度，包括药明康德 、凯莱英 、微创机器人 及精锋医疗 。另外，该行将爱康医疗 评级升至“买入”，反映其执行力重启、利润率改善及中期能见度更清晰，并将微泰医疗 升级至“中性”，因国内竞争影响优于预期，且有序达成2026年指引。前者受累于持续的VBP相关利润压力及短期增长乏力，后者收入加速回升但仍不明朗，上行空间有限。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"603259":"药明康德","06821":"凯莱英","BK1100":"医疗保健设备","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU0456842615.SGD":"JPMorgan Funds - Emerging Markets Equity A (acc) SGD","CDMO":"Avid Bioservices, Inc.","LU2045819591.USD":"Natixis WCM Global Emerging Markets Equity R/A USD","LU1997245177.USD":"安联神洲A股基金","BK4139":"生物科技","LU0052750758.USD":"富兰克林中国基金A Acc","LU0320764599.SGD":"FTIF - Templeton China A Acc SGD","BK1583":"高瓴概念","BK0239":"医药制造","LU0173614495.USD":"富达中国焦点A","LU0708995583.HKD":"TEMPLETON CHINA \"A\" (HKD) ACC","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","02252":"微创机器人-B","LU2125910500.SGD":"Natixis WCM Global Emerging Markets Equity H-R/A SGD","LU0287142896.SGD":"Fidelity China Focus A-SGD","LU1934453819.USD":"AB CHINA A SHARES EQUITY PORTFOLIO \"A\" (USD) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU2495084118.USD":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","LU1979443071.USD":"AB CHINA A SHARES EQUITY PORTFOLIO \"AD\" (USDHDG) INC","BK0216":"研究试验","LU0348766576.USD":"ALLIANZ LITTLE DRAGONS \"A\" (USD) INC","LU1046422090.SGD":"Fidelity Pacific A-SGD","LU1997244956.HKD":"ALLIANZ CHINA A-SHARES \"AT\" (HKD) ACC A","LU0348767384.USD":"ALLIANZLITTLE DRAGONS \"A\" (USD) ACC","BK1589":"北水核心资产","01789":"爱康医疗","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","BK1585":"昨日强势股","02359":"药明康德","BK1617":"AI医疗","BK1141":"生命科学工具和服务","BK1576":"医药外包概念","BK0132":"高送转概念","002821":"凯莱英","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","BK1191":"制药","02675":"精锋医疗-B","BK1222":"医疗保健用品","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU1808992512.USD":"AB ALL CHINA EQUITY PORTFOLIO \"A\" (USD) ACC","01066":"威高股份"},"translate_title":"Goldman Sachs: Mainland CDMO sector is stable and optimistic about WuXi AppTec (02359), Asymchem (06821), etc.","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"603259":1.5,"02359":1.5,"02675":0.9,"01789":0.9,"002821":1.5,"06821":1.5,"01066":0.9,"02252":0.9,"CDMO":1.5},"content_text":"智通财经APP获悉，高盛就内地医药行业发布研报称，CDMO企业的业绩反映该板块的周期维持稳健，能见度日益取决于后期及商业化项目的敞口，而非早期融资条件。而AI亦未有对订单量、订单积压质量或定价造成结构性破坏。相反，医疗器械与医疗服务企业的业绩印证了不同股份的复苏进度参差。虽然大部分集中带量采购(VBP)与医保支付方式改革(DRG/DIP)的阻力似乎已被消化，但销量复苏、定价能力与盈利能见度仍存在差异。股份方面，该行对评级为“买入”的股份持更正面态度，包括药明康德(02359) 、凯莱英(06821) 、微创机器人(02252) 及精锋医疗(02675) 。另外，该行将爱康医疗(01789) 评级升至“买入”，反映其执行力重启、利润率改善及中期能见度更清晰，并将微泰医疗(02235) 升级至“中性”，因国内竞争影响优于预期，且有序达成2026年指引。相反，该行对威高股份(01066) 及通策医疗(600763.SH)持谨慎态度，两者分别降级至“中性”及“沽售”。前者受累于持续的VBP相关利润压力及短期增长乏力，后者收入加速回升但仍不明朗，上行空间有限。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}